Anti-Heat Shock Protein 90 Homolog therapeutic antibody (Pre-made Efungumab biosimilar,scFv) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Efungumab (trade name Mycograb) was a drug developed by NeuTec Pharma (a subsidiary of Novartis), intended to treat candidemia (a bloodstream infection caused by pathogenic yeast) in combination with amphotericin B. The European Medicines Agency has twice refused to grant marketing authorization for Mycograb, citing product safety and quality issues.

Order information

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-167-1mg	1mg	3090
GMP-Bios-ab-167-10mg	10mg	21890
GMP-Bios-ab-167-100mg	100mg	148000
GMP-Bios-ab-167-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Anti-Heat Shock Protein 90 Homolog therapeutic antibody (Pre-made Efungumab biosimilar,scFv)
INN Name	Efungumab
Target	Heat Shock Protein 90 Homolog
Format	scFv
Derivation	Human
Species Reactivity	Human
CH1 Isotype	na
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-III
Est. Status	Discontinued
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2006
Year Recommended	2007
Companies	NeuTec Pharma
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Breast cancer;Candidiasis
Development Tech	na